Pharmacology

Acute coronary syndromes

Abbreviated Dual Antiplatelet Therapy with Prasugrel: 4D-ACS

The optimal duration of dual antiplatelet therapy (DAPT) in acute coronary syndrome (ACS) remains subject to controversy....

Dr. Omar Tupayachi - 3 August, 2025

Learn More

Aorta

Statins and Small Abdominal Aortic Aneurysms: Unexpected Aid?

Courtesy of Dr. Juan Manuel Pérez. Abdominal aortic aneurysms (AAA) entail high morbimortality in case of rupture, and...

Dr. Juan Manuel Pérez - 21 July, 2025

Learn More

Acute coronary syndromes

Aspirin vs. Clopidogrel Monotherapy After 1 Month of ACS: Subgroup Analysis Based on Bleeding Risk and MI Type

Current guidelines still recommend dual antiplatelet therapy (DAPT) for 12 months following percutaneous coronary intervention (PCI) as...

Dr. Andrés Rodríguez - 11 June, 2025

Learn More

Antiplatelet

Is it Time to Give Up Aspirin after PCI in High Bleeding Risk Patients? A Critical Analysis of STOPDAPT-3

Short dual antiplatelet treatment (DAPT) has been adopted in high bleeding risk patients to minimize bleeding complications...

Dr. Juan Manuel Pérez - 27 May, 2025

Learn More

Acute coronary syndromes

EuroPCR 2025 | 4D-ACS Study: One-Month Dual Antiplatelet Therapy Followed by Low-Dose Prasugrel Monotherapy

While dual antiplatelet therapy (DAPT) has long been the standard treatment for managing patients with acute coronary...

Dr. Andrés Rodríguez - 26 May, 2025

Learn More

Antiplatelet

Cangrelor in Acute and Chronic Coronary Syndromes: The POMPEII Registry

Platelet inhibition during and after coronary angioplasty is essential to prevent peri- and post-procedural ischemic events. To...

Dr. Omar Tupayachi - 21 May, 2025

Learn More

Acute coronary syndromes

Pretreatment with DAPT in Acute Coronary Syndrome: An Ongoing Debate?

In acute coronary syndrome (ACS) dual antiplatelet therapy (DAPT) has become a fundamental pillar after percutaneous coronary...

Dr. Omar Tupayachi - 29 April, 2025

Learn More

Antiplatelet

SMART-CHOICE 3 | Efficacy and Safety of Clopidogrel vs Aspirin Monotherapy in High Risk Patients after Percutaneous Coronary Intervention

Courtesy of Dr. Juan Manuel Pérez. After post percutaneous coronary intervention (PCI) standard duration dual antiplatelet therapy (DAPT),...

Dr. Juan Manuel Pérez - 14 April, 2025

Learn More

Abbreviated Dual Antiplatelet Therapy with Prasugrel: 4D-ACS

Statins and Small Abdominal Aortic Aneurysms: Unexpected Aid?

Aspirin vs. Clopidogrel Monotherapy After 1 Month of ACS: Subgroup Analysis Based on Bleeding Risk and MI Type

Is it Time to Give Up Aspirin after PCI in High Bleeding Risk Patients? A Critical Analysis of STOPDAPT-3

EuroPCR 2025 | 4D-ACS Study: One-Month Dual Antiplatelet Therapy Followed by Low-Dose Prasugrel Monotherapy

Cangrelor in Acute and Chronic Coronary Syndromes: The POMPEII Registry

Pretreatment with DAPT in Acute Coronary Syndrome: An Ongoing Debate?

SMART-CHOICE 3 | Efficacy and Safety of Clopidogrel vs Aspirin Monotherapy in High Risk Patients after Percutaneous Coronary Intervention

Last News

Coronary Perforations and Use of Covered Stents: Safe and Effective Long-Term Strategy?

Is it really necessary to monitor all patients after TAVR?

Is it really necessary to monitor all patients after TAVR?

Institutional News

Watch Again: Pulmonary Embolism in 2025 — Risk Stratification and Novel Therapeutic Approaches

Watch Again: SELUTION – Sirolimus-Eluting Balloon for De Novo Coronary Lesions – New Evidence and Clinical Perspectives

25/11 – SOLACI Webinar: Pulmonary Embolism in 2025 – Risk Stratification and Novel Therapeutic Approaches

Access